Ken Frazier to become chair of the Transcarent Board of Directors, leading the organization into the future. Ken Frazier to lead Transcarent Board of Directors as Chair, ensuring a bright future for the organization.

Frazier's expertise and leadership skills make him vital to Transcarent's future success.

April 11th 2023.

Ken Frazier to become chair of the Transcarent Board of Directors, leading the organization into the future.

Ken Frazier to lead Transcarent Board of Directors as Chair, ensuring a bright future for the organization.
Today, Transcarent announced the addition of healthcare industry leader Ken Frazier to their board of directors - a milestone that marks the company's commitment to making high-quality, affordable care accessible to everyone.



Ken Frazier, who recently served as the Executive Chairman of Merck and is now the chairman of General Catalyst’s Health Assurance Initiatives, brings an unmatched level of experience and business acumen to the table.



Glen Tullman, CEO of Transcarent, said, “Ken’s experience in healthcare and business is unparalleled. His decision to join our Board further validates Transcarent’s mission to solve the industry’s most challenging issues.”



Ken Frazier is also a tireless advocate for social justice and economic inclusion. His commitment to OneTen, a coalition dedicated to upskilling and hiring one million Black Americans into family-sustaining jobs, is an admirable example of his passion for equal opportunity.



Frazier commented, “I’m excited to join the Transcarent Board and to be part of an organization that is uniquely positioned to not only improve health and care delivery, but will do so in a way that makes it more equitable for the individual as well as their employer.”



The appointment of Ken Frazier to Transcarent's board of directors is an exciting step forward for the company and a positive change for the future of healthcare.

[This article has been trending online recently and has been generated with AI. Your feed is customized.]

 0
 0

0 Comments